P. Frankel

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

A. Krishnan, T. Schultheiss, J. Wong, 2010, Clinical Cancer Research.

Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib

P. Frankel, T. Synold, P. Twardowski, 2008, Cancer investigation.

Baseline selenium and prostate cancer risk: comments and open questions.

P. Frankel, R. Parker, P. Whanger, 2014, Journal of the National Cancer Institute.

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

L. Leong, S. Wilczynski, P. Frankel, 2018, Clinical Cancer Research.

Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is premature.

P. Frankel, P. Twardowski, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.

J. Doroshow, W. Ye, L. Leong, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.

P. Frankel, G. Somlo, J. Yim, 2015, Breast.

Jonathan C. Cheng, An Liu, T. Schultheiss, 2019, International journal of radiation oncology, biology, physics.

Slice-illuminated optical projection tomography

Samuel P. X. Davis, S. Arridge, P. Frankel, 2018, Optics letters.

In vivo multiplexed OPT and FLIM OPT of an adult zebrafish cancer disease model

S. Arridge, Y. Alexandrov, M. Dallman, 2016 .

Fluorescence lifetime optical projection tomography and FRET applied to visualizing apoptosis in live zebrafish larvae

Y. Alexandrov, M. Dallman, P. Frankel, 2016 .

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer

S. Narod, P. Frankel, C. Villarreal-Garza, 2021, Cancer research communications.

Sensitive Characterization of Circulating Tumor Cells for Improving Therapy Selection

P. Frankel, G. Somlo, S. Lau, 2010 .

Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells.

P. Frankel, A. Arrington, M. Yip, 2015, Cancer letters.

A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction

M. Fakih, P. Frankel, J. Gong, 2019, The oncologist.

Structural studies of neuropilin‐2 reveal a zinc ion binding site remote from the vascular endothelial growth factor binding pocket

P. Frankel, S. Djordjević, R. Rana, 2016, The FEBS journal.

N‐Terminal Modification of VEGF‐A C Terminus‐Derived Peptides Delineates Structural Features Involved in Neuropilin‐1 Binding and Functional Activity

P. Frankel, John F. Martin, I. Evans, 2014, Chembiochem : a European journal of chemical biology.

Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas

P. Frankel, I. Evans, C. Pellet-Many, 2011, The Biochemical journal.

Chondroitin sulphate‐modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas‐mediated pathway

P. Frankel, P. Lehtolainen, C. Pellet-Many, 2008, EMBO reports.

Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.

Y. Yen, L. Leong, P. Frankel, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

D. Gandara, P. Frankel, J. Hu, 2015, British Journal of Cancer.

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia

J. Wright, P. Frankel, S. Forman, 2011, Leukemia.

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

D. Gandara, H. Lenz, L. Appleman, 2019, Cancer Chemotherapy and Pharmacology.

A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design

Ian R. Lanza, S. Cherry, L. Nardo, 2021 .

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer

S. Neuhausen, P. Frankel, S. Pal, 2019, Journal of cancer research and therapeutic oncology.

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

Anna M. Acosta, P. Frankel, J. Zaia, 2022, iScience.

Endosome-to-Plasma Membrane Recycling of VEGFR2 Receptor Tyrosine Kinase Regulates Endothelial Function and Blood Vessel Formation

P. Frankel, C. Pellet-Many, I. Zachary, 2014, Cells.

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers

J. Waisman, P. Frankel, D. Diamond, 2018, Clinical and Translational Oncology.

Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.

C. Lau, M. Kortylewski, P. Frankel, 2015, The Journal of urology.

Antagonistic effects of protein kinase C alpha and delta on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor.

A. Hornia, T. Sukezane, T. Joseph, 1999, Molecular and cellular biology.

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

A. Nademanee, P. Frankel, S. Forman, 2015, Haematologica.

Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement

P. Frankel, S. Okuno, W. Chow, 2022, Journal of oncology.

A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity

L. Leong, B. Paz, P. Frankel, 2019, Cancer Chemotherapy and Pharmacology.

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Y. Yen, J. Doroshow, L. Leong, 2007, Clinical Cancer Research.

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.

M. Milowsky, William Y. Kim, S. Srinivas, 2021, JAMA oncology.

Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.

Mark E. Davis, Y. Yen, M. Fakih, 2017, Journal of Gastrointestinal Oncology.

Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma

M. Fakih, L. Leong, P. Frankel, 2016, Oncology.

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

Y. Yen, J. Doroshow, L. Leong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology.

S. Groshen, P. Frankel, J. Longmate, 2020, Current problems in cancer.

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

J. Issa, P. Marks, A. Yang, 2014, British journal of haematology.

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

J. Doroshow, D. Gandara, P. Gumerlock, 2005, Clinical Cancer Research.

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

E. Perez, J. Doroshow, V. Israel, 2001, Cancer Chemotherapy and Pharmacology.

A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

R. Jandial, P. Frankel, B. Badie, 2013, European journal of cancer.

Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study

Jinha M. Park, J. Bading, P. Frankel, 2021, The Journal of Nuclear Medicine.

Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies

S. Groshen, P. Frankel, S. Sampath, 2020, JAMA network open.

Mitogenic phospholipase D activity is restricted to caveolin-enriched membrane microdomains.

T. Joseph, P. Frankel, D. A. Foster, 2000, Biochemical and biophysical research communications.

A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent

P. Frankel, B. Badie, S. Mi, 2014, Journal of Neuro-Oncology.

First-In-Human Pilot PET Immunoimaging Study of 64Cu-Anti-Carcinoembryonic Antigen Monoclonal Antibody (hT84.66-M5A) in Patients with Carcinoembryonic Antigen-Producing Cancers.

Yi-Jen Chen, J. Wong, A. Wu, 2022, Cancer biotherapy & radiopharmaceuticals.

Ral and Rho-dependent activation of phospholipase D in v-Raf-transformed cells.

U. Rapp, T. Joseph, P. Frankel, 1999, Biochemical and biophysical research communications.

Activation of gene expression by a non-transforming unmyristylated-SH3-deleted mutant of Src is dependent upon Tyr-527.

P. Frankel, D. A. Foster, M. Curto, 1997, Biochemical and biophysical research communications.

Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design

M. Fakih, J. Jones, P. Frankel, 2022, Pleura and peritoneum.

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Y. Yen, P. Frankel, Kenneth K. Chan, 2016, Leukemia & lymphoma.

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced SolidTumors : ACalifornia Cancer Consortium Phase I Pharmacokinetic andMolecular Correlative Trial

J. Doroshow, D. Gandara, P. Gumerlock, 2005 .

Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.

L. Leong, P. Frankel, G. Somlo, 2009, Anticancer research.

Functional association between Arf and RalA in active phospholipase D complex.

R. Kahn, P. Frankel, D. A. Foster, 1998, Proceedings of the National Academy of Sciences of the United States of America.

PDGF controls contact inhibition of locomotion by regulating N-cadherin during neural crest migration

R. Mayor, P. Frankel, A. Frolov, 2017, Development.

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

M. Maitland, D. Gandara, S. Ramalingam, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

P. Frankel, S. Forman, J. Tuscano, 2014 .

A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.

David D. Smith, P. Frankel, M. Senthil, 2014, Thrombosis research.

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

A. Nademanee, P. Frankel, S. Forman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

P. Frankel, J. Tuscano, C. Costello, 2019, Blood.

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Y. Yen, J. Doroshow, D. Gandara, 2002, Cancer Chemotherapy and Pharmacology.

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

J. Waisman, J. S. Lee, P. Frankel, 2022, Cancers.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.

Y. Yen, J. Doroshow, L. Leong, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.

J. Trent, T. Dorff, S. Highlander, 2021 .

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A. Nademanee, D. Gandara, P. Frankel, 2007 .

RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.

J. Aguirre-Ghiso, E. D. Bal de Kier Joffé, P. Frankel, 2001, Biochemical and biophysical research communications.

Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.

A. Chen, D. Gandara, M. Goetz, 2014 .

RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases

Zhimin Lu, J. Aguirre-Ghiso, P. Frankel, 1999, Oncogene.

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

J. Doroshow, D. Gandara, H. Lenz, 2012, Investigational New Drugs.

Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials

C. Lau, D. Sadava, Shiuan Chen, 2023, Cancers.

Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation

P. Frankel, J. Ito, S. Forman, 2015, European journal of haematology.

A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid‐derived suppressor cells for Agaricus bisporus–induced prostate‐specific antigen responses

N. Kanaya, Shiuan Chen, P. Frankel, 2015, Cancer.

Selective activation of protein kinase C isoforms by v-Src.

P. Frankel, D. A. Foster, Q. Zang, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

J. Waisman, Jian Ye, J. S. Lee, 2021, Journal for ImmunoTherapy of Cancer.

Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient mice.

Lixin Yang, P. Frankel, F. Chu, 2005, The Journal of nutrition.

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.

C. Presant, J. S. Lee, P. Frankel, 2021, European journal of cancer.

Neuropilins: structure, function and role in disease.

P. Frankel, C. Pellet-Many, I. Zachary, 2008, The Biochemical journal.

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Jeff Trent, T. Dorff, S. Highlander, 2022, Nature Medicine.

Clinicopathologic significance of synchronous and metachronous adenomas in colorectal cancer.

Y. Yen, P. Frankel, D. David, 2005, Clinical colorectal cancer.

UC Office of the President Recent Work Title De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer

Weiying Zhou, Yun Yen, John J Rossi, 2012 .

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.

J. Waisman, J. S. Lee, P. Frankel, 2020, The oncologist.

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

T. Zimmerman, Helen X. Chen, J. Doroshow, 2011, British journal of haematology.

Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2− and ER+HER2+) breast cancers

P. Chu, N. Kanaya, Shiuan Chen, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma.

Y. Yen, Xiyong Liu, P. Chu, 2003, The American journal of pathology.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Y. Yen, J. Doroshow, D. Gandara, 2009, Cancer Chemotherapy and Pharmacology.

PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial

M. Fakih, Y. Fong, P. Frankel, 2021, Annals of Surgical Oncology.

Neuropilin-1 Signaling through p130Cas Tyrosine Phosphorylation Is Essential for Growth Factor-Dependent Migration of Glioma and Endothelial Cells

P. Frankel, I. Evans, C. Pellet-Many, 2011, Molecular and Cellular Biology.

SARS-CoV-2 Specific Monoclonal Antibody for the Treatment of Mild-to-Moderate COVID-19 in Cancer Patients: A Single-center Experience

P. Frankel, R. Taplitz, D. Nanayakkara, 2021, Journal of Infectious Diseases.

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

D. Gandara, S. Ramalingam, P. Frankel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

J. Kirkwood, A. Chen, D. Gandara, 2011, Clinical Cancer Research.

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

David D. Smith, James H. Doroshow, Paul Frankel, 2008, Clinical Cancer Research.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

A. Chen, D. Gandara, M. Goetz, 2017, Clinical Cancer Research.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.

H. Wakelee, J. Nieva, J. Riess, 2012, Lung cancer.

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival

P. Frankel, J. Mortimer, P. Aoun, 2019, PloS one.

Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.

A. Chen, D. Gandara, M. Goetz, 2013 .

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Multigene assessment of genetic risk for women for two or more breast cancers

T. Slavin, P. Frankel, M. Daly, 2021, Breast Cancer Research and Treatment.

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.

P. Chu, P. Frankel, G. Budd, 2010, Anticancer research.

Stereotactic body radiation therapy to the prostate bed: results of a phase I dose escalation trial.

An Liu, J. Wong, P. Frankel, 2019, International journal of radiation oncology, biology, physics.

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma

P. Frankel, M. Milhem, S. Okuno, 2019, Cancer.

NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

J. Kirkwood, A. Chen, H. Tawbi, 2018, Cancer.

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

S. Kane, L. Leong, C. Russell, 2012, Breast Cancer Research and Treatment.

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

J. Garber, S. Neuhausen, N. Tung, 2012, Cancer genetics.

Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival.

J. Garber, S. Neuhausen, U. Matulonis, 2010 .

A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.

S. Highlander, J. Waisman, J. S. Lee, 2020, The oncologist.

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

P. Frankel, H. Andersen, D. Diamond, 2022, NPJ vaccines.

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

P. Frankel, H. Andersen, D. Diamond, 2021, npj Vaccines.

Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.

P. Frankel, G. Somlo, S. Forman, 2022, Transplantation and cellular therapy.

Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors

M. Kortylewski, Xiwei Wu, P. Frankel, 2015, Clinical Cancer Research.

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

K. Foon, P. Frankel, J. Tuscano, 2014, Leukemia & lymphoma.

Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients.

Roger R. Wang, G. Srinivasan, P. Frankel, 2019, JCI insight.

Phospholipase D and RalA Cooperate with the Epidermal Growth Factor Receptor To Transform 3Y1 Rat Fibroblasts

Zhimin Lu, A. Hornia, T. Sukezane, 2000, Molecular and Cellular Biology.

Differential gene expression and AKT targeting in triple negative breast cancer

Yate-Ching Yuan, P. Chu, F. Lin, 2019, Oncotarget.

The Role of the Neuropilins in Tumour Angiogenesis and Tumour Progression

C. Milagre, P. Frankel, Marwa Salah Mahmoud, 2017 .

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Y. Yen, L. Leong, P. Frankel, 2019, Cancer treatment and research communications.

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study

D. Gandara, P. Frankel, J. Tuscano, 2018, British journal of haematology.

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Resident memory CD 8 + T cells within cancer islands mediate survival in breast cancer patients

Roger R. Wang, G. Srinivasan, P. Frankel, 2019 .

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies

Y. Yen, J. Doroshow, L. Leong, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Tianhong Li, Sanjiv S. Agarwala, Scott D. Christensen, 2010, Investigational New Drugs.

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

Yun Yen, James H. Doroshow, Adam Mamelak, 2010, Cancer Chemotherapy and Pharmacology.

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

J. Doroshow, L. Leong, P. Frankel, 2002, British Journal of Cancer.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

A. Krishnan, J. Wright, P. Frankel, 2006 .

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

D. Gandara, E. Heath, W. Stadler, 2010, Urology.

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR products

Y. Yen, J. Doroshow, D. Gandara, 2003, Journal of clinical laboratory analysis.

Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET

J. Bading, P. Conti, P. Frankel, 2014, The Journal of Nuclear Medicine.

Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients

M. Kortylewski, P. Frankel, S. Sampath, 2018, Oncotarget.

Accelerated Optical Projection Tomography Applied to In Vivo Imaging of Zebrafish

Simon Arridge, Paul M. W. French, Teresa Correia, 2015, PloS one.

Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial

A. Amini, L. Leong, P. Frankel, 2022, Cancers.

Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin.

J. Kirkwood, P. Frankel, K. Margolin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human study of neural stem cells (NSCs) expressing cytosine deaminase (CD) in combination with 5-fluorocytosine (5-FC) in patients with recurrent high-grade glioma.

J. Frank, R. Moats, P. Frankel, 2013 .

Sentinel lymph node B cells can predict disease-free survival in breast cancer patients

D. Krag, K. Blenman, P. Frankel, 2018, npj Breast Cancer.

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Nademanee, D. Gandara, P. Frankel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tuning the cell cycle: a model based on averaging

P. Frankel, 2002, Cell proliferation.

Vorinostat (suberoylanilide hydroxamic acid) as salvage therapy in metastatic breast cancer (MBC): A California Cancer Consortium phase II study

D. Gandara, L. Leong, P. Frankel, 2007 .

Outcomes of Salvage Percutaneous Biliary Drainage after Occlusion of Endoscopic Stents.

John J. Park, P. Frankel, A. Dagis, 2017, Journal of vascular and interventional radiology : JVIR.

Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies primarily confined to the peritoneal cavity.

L. Leong, P. Frankel, I. Paz, 2015 .

Dosimetric predictors of genitourinary toxicity from a phase I trial of prostate bed stereotactic body radiation therapy.

P. Frankel, S. Sampath, Richard Li, 2020, Practical radiation oncology.

Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling

U. Rapp, T. Joseph, P. Frankel, 2002, Oncogene.

Growth of the Social #RadOnc Network on Twitter.

A. Amini, B. Kavanagh, P. Frankel, 2020, Practical radiation oncology.

Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis

S. Gordon, P. Frankel, A. Salama, 2023, Annals of the Rheumatic Diseases.

Combining pembrolizumab and palliative radiotherapy in gastroesophageal cancer to enhance anti-tumor T-cell response and augment the abscopal effect.

Yi-Jen Chen, M. Fakih, P. Frankel, 2017 .

Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).

A. Chen, D. Gandara, M. Goetz, 2015 .

Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy.

P. Frankel, S. Pal, G. Somlo, 2012, The journal of supportive oncology.

Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium

D. Gandara, D. Quinn, P. Frankel, 2007, Journal of Cancer Research and Clinical Oncology.

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis

Roger R. Wang, P. Frankel, Peter P. Lee, 2020, PloS one.

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.

J. Waisman, P. Frankel, J. Mortimer, 2021 .

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

L. Leong, P. Frankel, M. Cristea, 2012, Cancer Chemotherapy and Pharmacology.

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Y. Yen, J. Doroshow, L. Leong, 2004, Journal of Clinical Oncology.

Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial.

D. Gandara, E. Heath, W. Stadler, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer

Jinha M. Park, J. Bading, R. Rockne, 2018, The Journal of Nuclear Medicine.

A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy

M. Fakih, S. Sentovich, P. Frankel, 2017, Oncotarget.

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

A. Sette, P. Frankel, J. Zaia, 2022, The Lancet Microbe.

Parametric models for accelerated and long‐term survival: a comment on proportional hazards

P. Frankel, J. Longmate, 2002, Statistics in medicine.

Validation and feasibility of a caloric expenditure measuring device in women with early-stage breast cancer

P. Frankel, C. Dieli-Conwright, J. Mortimer, 2014, Supportive Care in Cancer.

A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.

J. Waisman, P. Frankel, G. Somlo, 2019, Journal of Clinical Oncology.

A Heat-Shock Protein Axis Regulates VEGFR2 Proteolysis, Blood Vessel Development and Repair

N. Yuldasheva, M. Kearney, P. Frankel, 2012, PloS one.

Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC)

P. Frankel, G. Somlo, I. Paz, 2008 .

Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells

C. Milagre, S. Tsirka, P. Frankel, 2018, Journal of medicinal chemistry.

The tomato dark green mutation is a novel allele of the tomato homolog of the DEETIOLATED1 gene

I. Levin, P. Frankel, N. Gilboa, 2003, Theoretical and Applied Genetics.

Convolutional neural networks for reconstruction of undersampled optical projection tomography data applied to in vivo imaging of zebrafish

Seth Flaxman, Sunil Kumar, Yuriy Alexandrov, 2019, Journal of biophotonics.

Quantitative in vivo optical tomography of cancer progression & vasculature development in adult zebrafish

Simon Arridge, Sebastian Brandner, Teresa Correia, 2016, Oncotarget.

Visualising apoptosis in live zebrafish using fluorescence lifetime imaging with optical projection tomography to map FRET biosensor activity in space and time

Y. Alexandrov, M. Dallman, P. Frankel, 2016, Journal of biophotonics.

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

J. Doroshow, D. Gandara, H. Lenz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.

A. Krishnan, An Liu, T. Schultheiss, 2005 .

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer

J. Waisman, P. Frankel, G. Somlo, 2022, Cancer.

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

A. Krishnan, P. Frankel, G. Somlo, 2006, Bone Marrow Transplantation.

Optimal Anesthetic Regime for Motionless Three-Dimensional Image Acquisition During Longitudinal Studies of Adult Nonpigmented Zebrafish

Carole Wilson, Paul Frankel, Nicola Lockwood, 2017, Zebrafish.

A permutation test for a weighted Kaplan-Meier estimator with application to the nutritional prevention of cancer trial.

P. Frankel, J. Marshall, M. Reid, 2007, Contemporary clinical trials.

Improved antibody-guided surgery with a near-infrared dye on a PEGylated linker for CEA-positive tumors

Michael Bouvet, Robert M. Hoffman, John E. Shively, 2019, Journal of biomedical optics.

Sentinel lymph node B cells can predict disease-free survival in breast cancer patients

D. Krag, K. Blenman, P. Frankel, 2018, npj Breast Cancer.

Use of Large Language Models and Artificial Intelligence Tools in Works Submitted to Journal of Clinical Oncology.

P. Frankel, K. Miller, H. Burstein, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

A. Krishnan, T. Schultheiss, J. Wong, 2010, Clinical Cancer Research.

Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.

S. Groshen, W. Ye, P. Chu, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort.

Yi-Jen Chen, S. Wilczynski, P. Frankel, 2021 .

Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA

M. Fakih, P. Frankel, L. Rodriguez-Rodriguez, 2023, Annals of Surgical Oncology.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

J. Waisman, J. S. Lee, P. Frankel, 2023, Cancer Immunology, Immunotherapy.

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

M. Michaelson, M. Milowsky, William Y. Kim, 2021 .

Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863).

M. Maitland, D. Gandara, S. Ramalingam, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

N. Agarwal, J. Wong, P. Frankel, 2017, Cancer treatment and research communications.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer

Guihua Sun, Jinhui Wang, Yate-Ching Yuan, 2012, Journal of Translational Medicine.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

D. Gandara, E. Heath, W. Stadler, 2010, Urology.

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

D. Gandara, P. Mack, S. Gadgeel, 2015 .

A phase 1 study of p53MVA vaccine in combination with pembrolizumab.

J. Waisman, P. Frankel, D. Diamond, 2018 .

De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer

Guihua Sun, Jinhui Wang, Yate-Ching Yuan, 2012, Journal of Translational Medicine.